Why the study?
Does intravenous vasopressin V1 receptor antagonist alter blood pressure regulation during hypovolemic hypotension in normal subjects?
Does intravenous vasopressin V1 receptor antagonist alter blood pressure regulation during hypovolemic hypotension in normal subjects?
In contrast to animal studies, vasopressin does not appear to contribute to the maintenance of blood pressure during hypovolemic hypotension in humans.
Answers are grounded in this paper and cite their sources.
Vasopressin V1 blockade does not worsen LBNP hypotension in healthy subjects; challenges animal data and leaves open its role in clinical hypovolemia.
In animals subjected to hemorrhage, plasma arginine vasopressin concentrations increase to levels sufficient to cause vasoconstriction, thus attenuating the hypotensive response. The purpose of this study was to examine the contribution of vasopressin to blood pressure regulation during hypotension in humans. Hypotension was induced in twelve normal subjects by lower body negative pressure (LBNP) before and after intravenous administration of vasopressin V1 receptor antagonist. Before drug administration, LBNP reduced systolic blood pressure from 125 +/- 4 to 78 +/- 12 mmHg (P < 0.01) as vasopressin concentration increased from 2.9 +/- 0.6 to 17 +/- 6 pg/ml (P < 0.05). After administration of the vasopressin antagonist, LBNP reduced systolic blood pressure from 128 +/- 3 to 89 +/- 11 mmHg (P < 0.01). The hypotensive response to LBNP was not potentiated by inhibiting vasopressin's vasoconstrictive effects (P = NS). Thus hypotension causes marked increases in plasma vasopressin concentration. In contrast to findings in animal studies, however, vasopressin does not contribute to the maintenance of blood pressure during hypotension in humans.
No takes yet. Share an insight, caveat, or question.
Hirsch et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: